At least $RVXCF is one of the 37..... I picked
Post# of 98056
I picked TBIO two weeks in a row, thinking it had another pop in it....finally moved on, now watch TBIO explode this week.
Resverlogix has a chance to be absolutely massive imo with their lead compound in a phase III clinical trial for Diabetes Mellitus. Diabetes is nothing short of a world wide epidemic, and most with full blown insulin dependent diabetics, no matter how well they maintain their blood sugar levels, they're likely to suffer from a heart attack, stroke or even death.
Epigenetics is going to be a huge area in my opinion....turning genes off and on through things called writers and erasers has the potential to completely transform the pharma industry....